Yao Xiong1,2, Hongyan Wu3, Judy Xu1,2. 1. School of Public Administration, Southwestern University of Finance and Economics, Chengdu, 611130, China. 2. Center of Health Policy and Governance, Southwestern University of Finance and Economics, Chengdu, 611130, China. 3. School of Medicine and Health Management, Guizhou Medical University, Guiyang, 550025, China. why_vivian@163.com.
Abstract
PURPOSE: We aimed to conduct psychometric tests for the Chinese version of ICECAP-A and compare the differences between ICECAP-A and EQ-5D-3L for patients with T2DM and explore the relationship between clinical conditions and ICECAP-A through diabetes-related clinical indicators. METHODS: Data were collected from a sample of 492 Chinese T2DM patients. The reliability and validity of the ICECAP-A were verified. Exploratory factor analysis (EFA), correlation analysis and regression analysis were conducted for both the ICECAP-A and EQ-5D-3L. RESULTS: Our results show that the Chinese version of ICECAP-A has good internal consistency with an overall Cronbach's Alpha coefficient of 0.721. The mean scores of ICECAP-A and EQ-5D-3L are 0.85 vs. 0.94. A weak correlation (r = 0.116) was found between the ICECAP-A tariff and EQ-5D-3L utility. EFA showed that although the five dimensions of the ICECAP-A and EQ-5D-3L scales were loaded into two different factors respectively. However, the two scales captured different dimensions of quality of life and can complement each other. The ICECAP-A, EQ-5D-3L, and EQ-VAS scores showed differences across different socio-demographic characteristics and clinic conditions groups. CONCLUSION: The Chinese version of the ICECAP-A capability instrument can be for assessing outcomes in adults with T2DM. It may capture more dimensions of QoL than traditional Health-related QoL (HRQoL) instruments and may be useful for economic evaluations of health care and social care for people with T2DM or other chronic diseases.
PURPOSE: We aimed to conduct psychometric tests for the Chinese version of ICECAP-A and compare the differences between ICECAP-A and EQ-5D-3L for patients with T2DM and explore the relationship between clinical conditions and ICECAP-A through diabetes-related clinical indicators. METHODS: Data were collected from a sample of 492 Chinese T2DM patients. The reliability and validity of the ICECAP-A were verified. Exploratory factor analysis (EFA), correlation analysis and regression analysis were conducted for both the ICECAP-A and EQ-5D-3L. RESULTS: Our results show that the Chinese version of ICECAP-A has good internal consistency with an overall Cronbach's Alpha coefficient of 0.721. The mean scores of ICECAP-A and EQ-5D-3L are 0.85 vs. 0.94. A weak correlation (r = 0.116) was found between the ICECAP-A tariff and EQ-5D-3L utility. EFA showed that although the five dimensions of the ICECAP-A and EQ-5D-3L scales were loaded into two different factors respectively. However, the two scales captured different dimensions of quality of life and can complement each other. The ICECAP-A, EQ-5D-3L, and EQ-VAS scores showed differences across different socio-demographic characteristics and clinic conditions groups. CONCLUSION: The Chinese version of the ICECAP-A capability instrument can be for assessing outcomes in adults with T2DM. It may capture more dimensions of QoL than traditional Health-related QoL (HRQoL) instruments and may be useful for economic evaluations of health care and social care for people with T2DM or other chronic diseases.
Authors: Volker Foos; Ke Wang; Phil McEwan; Yanlei Zhang; Ping Xin; Xiaohua Jiang; Shuli Qu; Tengbin Xiong; Raf De Moor; Mafalda Ramos; Mark Lamotte; Linong Ji Journal: Value Health Reg Issues Date: 2018-11-09
Authors: Terry N Flynn; Elisabeth Huynh; Tim J Peters; Hareth Al-Janabi; Sam Clemens; Alison Moody; Joanna Coast Journal: Health Econ Date: 2013-11-20 Impact factor: 3.046
Authors: Paul Mark Mitchell; Hareth Al-Janabi; Sarah Byford; Willem Kuyken; Jeff Richardson; Angelo Iezzi; Joanna Coast Journal: BMC Psychiatry Date: 2017-02-02 Impact factor: 3.630
Authors: Pieter J Rohrbach; Alexandra E Dingemans; Brigitte A Essers; Eric F Van Furth; Philip Spinhoven; Catharina G M Groothuis-Oudshoorn; Janine A Van Til; M Elske Van den Akker-Van Marle Journal: Qual Life Res Date: 2021-08-31 Impact factor: 4.147
Authors: Isabella Busa; José M Ordóñez-Mena; Yaling Yang; Jane Wolstenholme; Stavros Petrou; Clare J Taylor; Chris A O'Callaghan; Simon D S Fraser; Maarten W Taal; Richard J McManus; Jennifer A Hirst; F D Richard Hobbs Journal: PLoS One Date: 2022-10-14 Impact factor: 3.752